Biochemical evaluation reveals potential strategies to bypass factor Xa inhibitors during bleeding episodes, highlighting the clinical demand for rapid-onset reversal agents.
Direct oral factor (F)Xa inhibitors are widely used as alternatives to conventional vitamin K antagonists in managing venous thromboembolism and nonvalvular atrial fibrillation. Unfortunately, bleeding-related adverse events remain a major concern in clinical practice. In case of bleeding or emergency surgery, rapid-onset reversal agents may be required to counteract the anticoagulant activity.
No takes yet. Share an insight, caveat, or question.
Schreuder et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: